Uncategorized

CHARLOTTESVILLE, Va., – AMPEL BioSolutions announced a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat inflammatory skin diseases, such as Lupus, Psoriasis, Atopic Dermatitis and Scleroderma. Revealed in the peer-reviewed journal Science Advances, the paper details AMPEL’s breakthrough machine learning approach to characterize disease activity from gene expression data obtained …

Caretaker Medical, a digital health leader in continuous “beat by beat” wireless patient monitoring technologies, announced that it has received FDA 510(k) Clearance for four new continuous hemodynamic parameters, adding cardiac output, stroke volume, heart rate variability, and left ventricular ejection time to its VitalStream™ non-invasive patient monitoring platform. This is the company’s 5th FDA …

RLS-0071 is ReAlta’s lead dual action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic-ischemic encephalopathy and other rare diseases Norfolk, VA, ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, today announced U.S. Food and …

“As then NIH Director Elias Zerhouni noted in 2004 while rejecting the first march in petition seeking to impose price controls on a successfully commercialized product: ‘… the extraordinary remedy of march-in rights is not an appropriate means of controlling prices.’ That was correct then and remains so today.” /IPWatchdog /As discussed previously, the critics are in full howl …

As students have shown great interest in the upcoming STEM2VA Summer Internship Program, we at VA Bio-Connect want to continue to invite employers to register as host sites for this great opportunity in providing experiential learning to those interested in the life sciences. With an application close date of Jan 31, 2022. There were over …

ATCC, the world’s premier biological materials management and standards organization, announced that it has been awarded a seven-year, Indefinite Delivery/Indefinite Quantity (IDIQ) contract with a ceiling value of $545 million by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). With this contract, ATCC will support NIAID’s …